by Lisa Willemse | May 21, 2014
> I’m not an academic, but I’ve been to many scientific conferences and read many more papers over the past 10 years or so. I know how important data is in research. I also know how important it is in communications (where visits, likes or shares are...
by Mark Curtis | May 14, 2014
. Welcome to your RM deal review for the month of April. There were two notable acquisitions this past month. NeoStem entered into an agreement to acquire California Stem Cell, while Aastrom acquired Sanofi’s regenerative medicine business. Read on to find out more....
by Mark Curtis | Apr 30, 2014
. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is...
by Roshan Yoganathan | Apr 17, 2014
Recently Revmedx, a pioneer in the biomaterial wound dressing field, made some waves with the commercialization of its product XStatTM . XStatTM received a lot of press because of its FDA approval for use against gunshot wounds and shrapnel-related injuries in the...
by Mark Curtis | Mar 11, 2014
. Welcome to your update from the clinic for the month of February! OncoMed is the leader in news this month with various Phase 1b trials for its cancer stem cell-targeting fusion protein. Immunocellular Therapeutics and StemCells Inc. file orphan drug designations...
by Stacey Johnson | Feb 21, 2014
. Dr. Robert Langer’s enthusiasm for the limitless promise of bioengineering is infectious. With his efforts and under his tutelage, one hopes that huge advances will be made in restoring movement to the paralyzed and curing the sick through, for example, more...
Comments